Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate

Doravirine is a nonnucleoside reverse transcriptase inhibitor that has been approved for the treatment of HIV-1. In a phase 1 trial, doravirine exposure was transiently decreased when treatment was started immediately after the cessation of efavirenz treatment. In a post hoc subgroup analysis of par...

Descripción completa

Detalles Bibliográficos
Autores principales: Greaves, Wayne, Wan, Hong, Yee, Ka Lai, Kandala, Bhargava, Vaddady, Pavan, Hwang, Carey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879224/
https://www.ncbi.nlm.nih.gov/pubmed/31548188
http://dx.doi.org/10.1128/AAC.01298-19
_version_ 1783473573314166784
author Greaves, Wayne
Wan, Hong
Yee, Ka Lai
Kandala, Bhargava
Vaddady, Pavan
Hwang, Carey
author_facet Greaves, Wayne
Wan, Hong
Yee, Ka Lai
Kandala, Bhargava
Vaddady, Pavan
Hwang, Carey
author_sort Greaves, Wayne
collection PubMed
description Doravirine is a nonnucleoside reverse transcriptase inhibitor that has been approved for the treatment of HIV-1. In a phase 1 trial, doravirine exposure was transiently decreased when treatment was started immediately after the cessation of efavirenz treatment. In a post hoc subgroup analysis of participants who switched from an efavirenz-based regimen to doravirine-lamivudine-tenofovir disoproxil fumarate in the phase 3 DRIVE-SHIFT trial, doravirine plasma levels at week 4 were similar to noninduced levels, and HIV-1 suppression was maintained at weeks 24 and 48.
format Online
Article
Text
id pubmed-6879224
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-68792242019-12-03 Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate Greaves, Wayne Wan, Hong Yee, Ka Lai Kandala, Bhargava Vaddady, Pavan Hwang, Carey Antimicrob Agents Chemother Antiviral Agents Doravirine is a nonnucleoside reverse transcriptase inhibitor that has been approved for the treatment of HIV-1. In a phase 1 trial, doravirine exposure was transiently decreased when treatment was started immediately after the cessation of efavirenz treatment. In a post hoc subgroup analysis of participants who switched from an efavirenz-based regimen to doravirine-lamivudine-tenofovir disoproxil fumarate in the phase 3 DRIVE-SHIFT trial, doravirine plasma levels at week 4 were similar to noninduced levels, and HIV-1 suppression was maintained at weeks 24 and 48. American Society for Microbiology 2019-11-21 /pmc/articles/PMC6879224/ /pubmed/31548188 http://dx.doi.org/10.1128/AAC.01298-19 Text en Copyright © 2019 Greaves et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Antiviral Agents
Greaves, Wayne
Wan, Hong
Yee, Ka Lai
Kandala, Bhargava
Vaddady, Pavan
Hwang, Carey
Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
title Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
title_full Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
title_fullStr Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
title_full_unstemmed Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
title_short Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
title_sort doravirine exposure and hiv-1 suppression after switching from an efavirenz-based regimen to doravirine-lamivudine-tenofovir disoproxil fumarate
topic Antiviral Agents
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879224/
https://www.ncbi.nlm.nih.gov/pubmed/31548188
http://dx.doi.org/10.1128/AAC.01298-19
work_keys_str_mv AT greaveswayne doravirineexposureandhiv1suppressionafterswitchingfromanefavirenzbasedregimentodoravirinelamivudinetenofovirdisoproxilfumarate
AT wanhong doravirineexposureandhiv1suppressionafterswitchingfromanefavirenzbasedregimentodoravirinelamivudinetenofovirdisoproxilfumarate
AT yeekalai doravirineexposureandhiv1suppressionafterswitchingfromanefavirenzbasedregimentodoravirinelamivudinetenofovirdisoproxilfumarate
AT kandalabhargava doravirineexposureandhiv1suppressionafterswitchingfromanefavirenzbasedregimentodoravirinelamivudinetenofovirdisoproxilfumarate
AT vaddadypavan doravirineexposureandhiv1suppressionafterswitchingfromanefavirenzbasedregimentodoravirinelamivudinetenofovirdisoproxilfumarate
AT hwangcarey doravirineexposureandhiv1suppressionafterswitchingfromanefavirenzbasedregimentodoravirinelamivudinetenofovirdisoproxilfumarate

Ejemplares similares